Frankfurter Institut für Klinische Krebsforschung IKF GmbH / Frankfurt Institute of Clinical Cancer Research
Research facility
Location:
Frankfurt am Main,
Germany (DE)
ISNI: -
Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”: [ESMO Open 9 (2024) 103703](S2059702924014728)(10.1016/j.esmoop.2024.103703) (2025)
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, et al.
Journal article, Erratum
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) (2024)
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, et al.
Journal article
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study (2022)
Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona MA, Kandulski A, et al.
Journal article
Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus (2012)
Forst T, Weber MM, Mitry M, Schon̈dorf T, Forst S, Tanis M, Pfuẗzner A, Michelson G
Journal article